Schear Investment Advisers LLC Makes New Investment in Medpace Holdings, Inc. $MEDP

Schear Investment Advisers LLC purchased a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 3,102 shares of the company’s stock, valued at approximately $1,490,000.

A number of other large investors have also made changes to their positions in MEDP. Geneos Wealth Management Inc. increased its position in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares in the last quarter. Steigerwald Gordon & Koch Inc. purchased a new position in Medpace in the 4th quarter valued at about $30,000. Elyxium Wealth LLC acquired a new stake in shares of Medpace during the 4th quarter worth about $30,000. Quarry LP acquired a new stake in shares of Medpace during the 3rd quarter worth about $35,000. Finally, Bayban purchased a new stake in shares of Medpace during the fourth quarter worth about $44,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on MEDP shares. BMO Capital Markets cut their price objective on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a research report on Friday, April 24th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Medpace in a research note on Thursday. Jefferies Financial Group reiterated a “hold” rating and issued a $515.00 price target (up from $490.00) on shares of Medpace in a report on Tuesday. Robert W. Baird reduced their price target on Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. Finally, Royal Bank Of Canada decreased their price objective on Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Three research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Medpace presently has an average rating of “Hold” and a consensus target price of $463.33.

Medpace Trading Down 1.8%

MEDP traded down $10.36 during trading on Tuesday, hitting $554.73. 80,232 shares of the company’s stock were exchanged, compared to its average volume of 354,389. Medpace Holdings, Inc. has a 1 year low of $306.70 and a 1 year high of $628.92. The stock has a 50 day moving average price of $457.31 and a 200 day moving average price of $496.24. The firm has a market cap of $15.84 billion, a P/E ratio of 34.76, a price-to-earnings-growth ratio of 2.83 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. The business had revenue of $706.60 million for the quarter, compared to the consensus estimate of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The business’s revenue for the quarter was up 26.5% compared to the same quarter last year. During the same quarter last year, the firm posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Analysts forecast that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total value of $7,357,050.00. Following the transaction, the general counsel directly owned 20,343 shares of the company’s stock, valued at $9,154,350. This trade represents a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 20.50% of the stock is owned by company insiders.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.